Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Condition:   Non-small Cell Lung Cancer Intervention:   Drug: DZD9008 and Probe drugs (midazolam, digoxin, rosuvastatin) Sponsor:   Dizal Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials